Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Maxcyte, Inc. filings on SEC EDGAR ↗
MaxCyte reported revenue of $10.2 million for the third quarter of 2026, a significant increase from $6.8 million in the prior year period. The company successfully reduced its quarterly net loss to $4.8 million from $12.4 million year-over-year, driven by higher gross profits and a substantial reduction in operating expenses across R&D and sales and marketing.
Maxcyte Signs $125M M&A Deal with Akron BioProducts LLC
MaxCyte has entered into a definitive agreement to acquire Akron BioProducts LLC for $105 million in cash, $20 million in deferred cash payments, and approximately 20.6 million shares of common stock. The acquisition of the GMP-grade reagent supplier is expected to nearly double MaxCyte's revenue and expand its cell therapy manufacturing offerings. The deal is expected to close before the end of 2026, subject to regulatory approvals.
Value
$125M
Counterparty
Akron BioProducts LLC
“Today, we announced our intention to acquire Akron Bio, a transformational moment for MaxCyte. I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value.”
MaxCyte announced preliminary Q3 2026 core business revenue of approximately $8.1 million, a 26% year-over-year increase. The company also raised its full-year 2026 total revenue guidance to approximately $34 million, up from the previous range of $30 million to $32 million, driven by accelerated instrument purchasing and milestone payments.